Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Profile

Christopher Lieu

Concepts (402)

Concepts are derived automatically from a person's publications.

Cloud
Categories
Timeline
Details
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Colorectal Neoplasms
51
2025
802
9.540
 Why?
Antineoplastic Combined Chemotherapy Protocols
24
2026
1787
2.790
 Why?
Colonic Neoplasms
8
2024
246
2.590
 Why?
Biomarkers, Tumor
20
2025
1251
2.060
 Why?
Molecular Targeted Therapy
9
2019
419
1.930
 Why?
Antineoplastic Agents
14
2021
2166
1.870
 Why?
Rectal Neoplasms
7
2023
152
1.650
 Why?
Antibodies, Monoclonal, Humanized
11
2025
852
1.630
 Why?
Bevacizumab
5
2024
139
1.620
 Why?
Benzimidazoles
3
2024
182
1.520
 Why?
Neoplasms
14
2025
2741
1.470
 Why?
Drug Resistance, Neoplasm
9
2024
830
1.130
 Why?
Mutation
15
2025
4013
1.060
 Why?
Age of Onset
9
2024
532
1.000
 Why?
Pancreatic Neoplasms
10
2025
882
0.990
 Why?
Neoplasm Staging
13
2025
1398
0.980
 Why?
Gastrointestinal Neoplasms
2
2025
76
0.960
 Why?
Tankyrases
1
2025
13
0.950
 Why?
Microsatellite Instability
10
2025
48
0.910
 Why?
Immunotherapy
4
2022
640
0.880
 Why?
Cetuximab
5
2025
105
0.860
 Why?
Neuroendocrine Tumors
6
2024
109
0.850
 Why?
Vascular Endothelial Growth Factor A
4
2020
550
0.850
 Why?
Circulating Tumor DNA
4
2025
35
0.800
 Why?
Proto-Oncogene Proteins p21(ras)
4
2019
263
0.790
 Why?
Oncologists
1
2023
44
0.790
 Why?
Proto-Oncogene Proteins B-raf
6
2024
222
0.760
 Why?
Fluorouracil
7
2025
206
0.750
 Why?
Humans
103
2026
141187
0.750
 Why?
Indoles
1
2025
429
0.730
 Why?
Antibodies, Monoclonal
6
2023
1448
0.700
 Why?
Wnt Signaling Pathway
3
2025
202
0.660
 Why?
Pyrimidinones
2
2024
114
0.650
 Why?
Middle Aged
43
2026
34434
0.650
 Why?
Aged
34
2026
24574
0.620
 Why?
Camptothecin
5
2025
122
0.620
 Why?
Pyridones
2
2024
176
0.610
 Why?
Leucovorin
6
2025
86
0.610
 Why?
Early Detection of Cancer
4
2025
441
0.610
 Why?
Neoplasm Metastasis
9
2025
674
0.590
 Why?
Piperidines
2
2017
216
0.570
 Why?
Colectomy
1
2019
107
0.570
 Why?
Adult
39
2026
39177
0.560
 Why?
Disease-Free Survival
7
2023
715
0.530
 Why?
Azetidines
1
2017
44
0.530
 Why?
Cyclosporine
1
2018
265
0.530
 Why?
Genetic Predisposition to Disease
4
2022
2363
0.530
 Why?
Terminology as Topic
1
2019
244
0.520
 Why?
Appendiceal Neoplasms
2
2020
29
0.510
 Why?
Carcinoma, Pancreatic Ductal
3
2025
277
0.500
 Why?
Male
45
2026
69783
0.480
 Why?
Medical Oncology
5
2023
316
0.460
 Why?
MAP Kinase Kinase Kinases
1
2015
72
0.460
 Why?
Adrenal Gland Neoplasms
3
2022
89
0.460
 Why?
Patient Rights
1
2015
11
0.460
 Why?
Kaplan-Meier Estimate
7
2025
908
0.460
 Why?
Therapies, Investigational
1
2015
18
0.450
 Why?
Female
45
2026
75515
0.450
 Why?
Drug and Narcotic Control
1
2015
29
0.450
 Why?
Chemotherapy, Adjuvant
5
2024
378
0.450
 Why?
Drugs, Investigational
1
2015
32
0.450
 Why?
Treatment Outcome
15
2025
11120
0.440
 Why?
Neovascularization, Pathologic
2
2013
296
0.440
 Why?
Precision Medicine
1
2019
434
0.440
 Why?
Healthcare Disparities
1
2021
666
0.440
 Why?
Relaxation Therapy
1
2014
19
0.420
 Why?
Leisure Activities
1
2014
30
0.420
 Why?
Adenocarcinoma
5
2023
892
0.410
 Why?
Stroke Rehabilitation
1
2014
42
0.410
 Why?
Pyrazines
2
2018
88
0.400
 Why?
Microsatellite Repeats
2
2024
159
0.390
 Why?
Clinical Trials as Topic
4
2025
1052
0.390
 Why?
Immunoglobulin G
1
2017
900
0.390
 Why?
Drug Evaluation, Preclinical
1
2013
196
0.390
 Why?
Drug Design
1
2013
168
0.380
 Why?
ErbB Receptors
5
2017
610
0.380
 Why?
Neoadjuvant Therapy
5
2023
419
0.360
 Why?
Xenograft Model Antitumor Assays
7
2025
898
0.350
 Why?
Carcinoma, Signet Ring Cell
1
2011
17
0.350
 Why?
Cell Transformation, Neoplastic
1
2013
333
0.350
 Why?
Terminal Care
1
2015
251
0.350
 Why?
Imidazoles
2
2024
244
0.330
 Why?
Fibroblast Growth Factors
1
2011
180
0.330
 Why?
Carcinoma, Squamous Cell
2
2026
642
0.330
 Why?
Dose-Response Relationship, Drug
3
2025
2064
0.320
 Why?
src-Family Kinases
1
2010
93
0.310
 Why?
Clinical Decision-Making
4
2024
339
0.310
 Why?
Genomics
4
2025
814
0.300
 Why?
Maximum Tolerated Dose
2
2025
206
0.300
 Why?
Patient Selection
3
2019
688
0.300
 Why?
Boronic Acids
1
2008
35
0.290
 Why?
Disease Management
4
2021
633
0.280
 Why?
Janus Kinase 2
1
2008
32
0.280
 Why?
Stomach Neoplasms
3
2022
118
0.280
 Why?
Myeloproliferative Disorders
1
2008
27
0.280
 Why?
Carboplatin
1
2008
146
0.280
 Why?
Etoposide
1
2008
163
0.280
 Why?
Organoplatinum Compounds
2
2024
49
0.260
 Why?
Carcinoembryonic Antigen
2
2024
38
0.260
 Why?
Aged, 80 and over
13
2026
7856
0.260
 Why?
Pathology, Molecular
2
2017
26
0.260
 Why?
Health Services Accessibility
1
2015
1016
0.260
 Why?
Cancer Survivors
2
2024
297
0.260
 Why?
Pathology, Clinical
2
2017
29
0.260
 Why?
Shock, Septic
1
2009
210
0.260
 Why?
Drug Administration Schedule
4
2019
771
0.250
 Why?
Ipilimumab
1
2026
35
0.240
 Why?
ras Proteins
2
2017
148
0.240
 Why?
Anus Neoplasms
1
2026
35
0.240
 Why?
CD47 Antigen
1
2025
45
0.230
 Why?
Neoplasms, Unknown Primary
1
2025
18
0.230
 Why?
Age Factors
5
2021
3292
0.230
 Why?
Diagnosis, Differential
1
2009
1498
0.220
 Why?
Oximes
1
2024
24
0.220
 Why?
Fluorescence Resonance Energy Transfer
1
2025
176
0.220
 Why?
CD3 Complex
1
2024
106
0.210
 Why?
United States
13
2025
15220
0.210
 Why?
Extracellular Vesicles
1
2025
152
0.200
 Why?
Antibodies, Bispecific
1
2024
60
0.200
 Why?
Metastasectomy
1
2023
20
0.200
 Why?
Young Adult
5
2024
13673
0.200
 Why?
Trifluridine
1
2022
3
0.200
 Why?
Signal Transduction
6
2018
5144
0.200
 Why?
Clinical Trials, Phase II as Topic
2
2022
73
0.200
 Why?
B7-H1 Antigen
2
2025
221
0.190
 Why?
Surgical Oncology
1
2022
28
0.190
 Why?
Neoplasm Grading
2
2024
316
0.190
 Why?
Empathy
1
2024
174
0.190
 Why?
Clinical Trials, Phase III as Topic
2
2022
106
0.190
 Why?
Genetic Testing
3
2022
460
0.190
 Why?
Databases, Factual
4
2017
1444
0.180
 Why?
Ovarian Neoplasms
2
2020
580
0.180
 Why?
Disease Models, Animal
4
2021
4404
0.180
 Why?
Membrane Proteins
3
2019
1154
0.180
 Why?
Cell Line, Tumor
5
2025
3469
0.180
 Why?
Survival Rate
6
2023
1970
0.180
 Why?
Retrospective Studies
10
2025
16273
0.180
 Why?
Chemoradiotherapy, Adjuvant
2
2023
44
0.180
 Why?
Prognosis
9
2025
4073
0.180
 Why?
Incidence
6
2022
2794
0.180
 Why?
Gene Regulatory Networks
1
2024
313
0.180
 Why?
Colorectal Neoplasms, Hereditary Nonpolyposis
1
2022
35
0.180
 Why?
Neoplasms, Multiple Primary
1
2022
59
0.180
 Why?
DNA
1
2008
1444
0.170
 Why?
Pheochromocytoma
1
2022
57
0.170
 Why?
Capecitabine
2
2022
42
0.170
 Why?
Meningioma
1
2022
95
0.170
 Why?
Heterografts
1
2021
134
0.170
 Why?
Congresses as Topic
2
2019
230
0.170
 Why?
Health Status Disparities
2
2020
297
0.160
 Why?
Artificial Intelligence
1
2024
334
0.160
 Why?
Practice Patterns, Physicians'
1
2009
1336
0.160
 Why?
Deoxycytidine
2
2024
192
0.160
 Why?
Immune System
1
2021
183
0.160
 Why?
Adenomatous Polyposis Coli Protein
1
2019
21
0.150
 Why?
Smad4 Protein
1
2019
35
0.150
 Why?
Area Under Curve
2
2018
324
0.150
 Why?
Retinal Vein
1
2019
13
0.150
 Why?
GTP Phosphohydrolases
1
2019
93
0.150
 Why?
Class I Phosphatidylinositol 3-Kinases
1
2019
97
0.150
 Why?
Tumor Suppressor Protein p53
2
2022
528
0.150
 Why?
Cell-Free Nucleic Acids
1
2019
33
0.150
 Why?
Disease Progression
4
2017
2793
0.140
 Why?
Vasculitis
1
2019
68
0.140
 Why?
Genes, ras
1
2018
95
0.140
 Why?
DNA Mismatch Repair
3
2024
47
0.140
 Why?
Neoplasm Transplantation
1
2018
250
0.140
 Why?
Proportional Hazards Models
3
2017
1261
0.140
 Why?
Retinal Diseases
1
2019
96
0.140
 Why?
Drug Combinations
2
2022
358
0.140
 Why?
Survivorship
1
2018
50
0.140
 Why?
Animals
11
2025
37657
0.140
 Why?
Cohort Studies
6
2020
5799
0.140
 Why?
Acneiform Eruptions
1
2017
1
0.140
 Why?
Risk Factors
6
2022
10438
0.140
 Why?
Patient Advocacy
1
2018
76
0.140
 Why?
Asthenia
1
2017
3
0.140
 Why?
Risk Assessment
2
2019
3490
0.140
 Why?
Evidence-Based Medicine
2
2019
750
0.130
 Why?
Population Surveillance
1
2021
481
0.130
 Why?
Drug Eruptions
1
2017
29
0.130
 Why?
Hypokalemia
1
2017
24
0.130
 Why?
Histone Deacetylase Inhibitors
1
2019
210
0.130
 Why?
Receptor, ErbB-3
1
2017
46
0.130
 Why?
MAP Kinase Kinase 1
1
2017
75
0.130
 Why?
Esophageal Neoplasms
1
2021
333
0.130
 Why?
Patient Compliance
1
2021
610
0.130
 Why?
Intercellular Signaling Peptides and Proteins
2
2015
388
0.130
 Why?
Programmed Cell Death 1 Receptor
1
2019
257
0.130
 Why?
Neoplasm Recurrence, Local
2
2023
1073
0.130
 Why?
Antineoplastic Agents, Immunological
1
2019
192
0.130
 Why?
Digestive System Neoplasms
1
2016
9
0.130
 Why?
Liver Neoplasms
2
2024
740
0.120
 Why?
Time Factors
2
2019
6956
0.120
 Why?
Triple Negative Breast Neoplasms
1
2019
200
0.120
 Why?
Edema
1
2016
131
0.120
 Why?
Insulin-Like Growth Factor I
1
2018
325
0.120
 Why?
Hospitals
1
2021
696
0.120
 Why?
Biomarkers
3
2023
4174
0.120
 Why?
Diabetic Neuropathies
1
2016
94
0.120
 Why?
GPI-Linked Proteins
1
2016
76
0.120
 Why?
Biliary Tract Neoplasms
1
2015
31
0.120
 Why?
Consensus
1
2019
704
0.120
 Why?
Device Approval
1
2015
21
0.120
 Why?
Patient Care Planning
1
2016
155
0.110
 Why?
Receptor, Notch1
1
2015
65
0.110
 Why?
Immunoblotting
1
2015
310
0.110
 Why?
Delivery of Health Care, Integrated
1
2018
289
0.110
 Why?
Neuralgia
1
2016
143
0.110
 Why?
Pancreas
1
2017
326
0.110
 Why?
Prevalence
1
2022
2772
0.110
 Why?
Gene Dosage
1
2015
141
0.110
 Why?
Administration, Oral
1
2017
803
0.110
 Why?
Health Behavior
1
2020
790
0.110
 Why?
Analgesics
1
2016
226
0.110
 Why?
Quality of Life
2
2024
2999
0.110
 Why?
Gene Expression Regulation
1
2024
2599
0.110
 Why?
Drug Approval
1
2015
92
0.110
 Why?
DNA Copy Number Variations
1
2015
176
0.110
 Why?
Immunoconjugates
1
2016
125
0.110
 Why?
Quinazolines
1
2015
250
0.110
 Why?
Adolescent
4
2024
22007
0.110
 Why?
Genetic Variation
1
2019
1000
0.110
 Why?
Phenotype
2
2021
3166
0.110
 Why?
United States Food and Drug Administration
1
2015
212
0.110
 Why?
Proto-Oncogene Proteins
1
2017
623
0.100
 Why?
Delivery of Health Care
1
2021
961
0.100
 Why?
Liquid Biopsy
2
2025
13
0.100
 Why?
Oligonucleotide Array Sequence Analysis
1
2015
761
0.100
 Why?
Lung Neoplasms
2
2024
2560
0.100
 Why?
beta Catenin
1
2015
258
0.100
 Why?
Mice
6
2025
18048
0.100
 Why?
Spinal Cord Injuries
1
2016
231
0.100
 Why?
National Cancer Institute (U.S.)
2
2025
48
0.100
 Why?
Patient-Centered Care
1
2018
550
0.100
 Why?
Randomized Controlled Trials as Topic
1
2019
1556
0.100
 Why?
Lymphocytes
1
2015
398
0.100
 Why?
Registries
1
2021
2135
0.090
 Why?
Protein Kinase Inhibitors
1
2018
914
0.090
 Why?
Risk
1
2014
904
0.090
 Why?
Angiogenesis Inhibitors
1
2013
230
0.090
 Why?
Ligands
1
2013
667
0.090
 Why?
Neoplasm, Residual
2
2022
132
0.080
 Why?
Prospective Studies
3
2022
7739
0.080
 Why?
Patient Care Team
1
2016
664
0.080
 Why?
Activities of Daily Living
1
2014
424
0.080
 Why?
Protein-Tyrosine Kinases
1
2013
431
0.080
 Why?
Mice, Nude
2
2024
691
0.080
 Why?
Apoptosis
3
2022
2574
0.080
 Why?
Streptococcaceae
1
2009
2
0.080
 Why?
Cytokines
2
2015
2098
0.080
 Why?
Clinical Medicine
1
2009
25
0.080
 Why?
Patient Satisfaction
1
2013
695
0.080
 Why?
Transcriptome
1
2015
1003
0.070
 Why?
Neutrophils
1
2015
1282
0.070
 Why?
Myositis
1
2009
52
0.070
 Why?
Chemoradiotherapy
2
2023
232
0.070
 Why?
Sulindac
1
2008
16
0.070
 Why?
Bortezomib
1
2008
53
0.070
 Why?
Mutation Rate
2
2019
29
0.070
 Why?
Taiwan
1
2008
46
0.070
 Why?
Combined Modality Therapy
1
2011
1243
0.070
 Why?
Nausea
1
2008
111
0.070
 Why?
Immunoenzyme Techniques
1
2008
209
0.070
 Why?
Multivariate Analysis
3
2017
1490
0.070
 Why?
Neutropenia
1
2008
157
0.070
 Why?
Fluphenazine
1
2007
5
0.070
 Why?
Risperidone
1
2007
30
0.070
 Why?
Nerve Fibers, Myelinated
1
2007
49
0.070
 Why?
Drug Therapy, Combination
1
2010
1040
0.070
 Why?
Food
1
2008
163
0.060
 Why?
Exons
1
2008
353
0.060
 Why?
Anemia
1
2008
177
0.060
 Why?
Fasting
1
2008
284
0.060
 Why?
Thrombocytopenia
1
2008
208
0.060
 Why?
Gastrectomy
2
2017
133
0.060
 Why?
Frontal Lobe
1
2007
162
0.060
 Why?
Propensity Score
2
2017
328
0.060
 Why?
Stroke
1
2014
1154
0.060
 Why?
Antipsychotic Agents
1
2007
212
0.060
 Why?
Polymerase Chain Reaction
1
2008
1056
0.060
 Why?
Postoperative Complications
1
2017
2797
0.050
 Why?
Loneliness
1
2024
50
0.050
 Why?
Survival Analysis
2
2017
1319
0.050
 Why?
Fluorescent Dyes
1
2025
324
0.050
 Why?
Delayed Diagnosis
1
2024
93
0.050
 Why?
Natural Language Processing
1
2024
99
0.050
 Why?
Oxidative Stress
1
2010
1330
0.050
 Why?
Cyclooxygenase 2 Inhibitors
1
2022
22
0.050
 Why?
Paclitaxel
1
2024
237
0.050
 Why?
G2 Phase Cell Cycle Checkpoints
1
2022
44
0.050
 Why?
Recombinant Fusion Proteins
1
2025
672
0.050
 Why?
Mice, Inbred BALB C
1
2025
1274
0.050
 Why?
Endothelial Growth Factors
1
2022
65
0.050
 Why?
Ataxia Telangiectasia Mutated Proteins
1
2022
66
0.050
 Why?
Resilience, Psychological
1
2024
129
0.050
 Why?
Organoids
1
2024
129
0.050
 Why?
Gallium Radioisotopes
1
2022
14
0.050
 Why?
Radioisotopes
1
2022
35
0.050
 Why?
Receptors, Peptide
1
2022
19
0.050
 Why?
Radionuclide Imaging
1
2022
116
0.050
 Why?
Intestinal Neoplasms
1
2022
31
0.050
 Why?
Neoplastic Syndromes, Hereditary
1
2021
43
0.040
 Why?
Positron Emission Tomography Computed Tomography
1
2022
109
0.040
 Why?
Radiopharmaceuticals
1
2022
188
0.040
 Why?
North America
1
2022
306
0.040
 Why?
Europe
1
2022
410
0.040
 Why?
Chimerism
1
2021
33
0.040
 Why?
Preventive Medicine
1
2021
40
0.040
 Why?
Lymphocyte Subsets
1
2021
88
0.040
 Why?
Surveys and Questionnaires
2
2024
5929
0.040
 Why?
Canada
1
2022
428
0.040
 Why?
Lymphoid Tissue
1
2021
81
0.040
 Why?
Hyaluronic Acid
1
2022
226
0.040
 Why?
Positron-Emission Tomography
1
2022
310
0.040
 Why?
Mice, SCID
1
2021
367
0.040
 Why?
Geography
1
2020
201
0.040
 Why?
Morbidity
1
2021
322
0.040
 Why?
Receptor Protein-Tyrosine Kinases
1
2022
231
0.040
 Why?
SEER Program
1
2020
220
0.040
 Why?
Mice, Inbred NOD
1
2021
600
0.040
 Why?
Spectrophotometry, Infrared
1
2019
54
0.040
 Why?
Sulfonamides
1
2022
520
0.040
 Why?
District of Columbia
1
2018
33
0.040
 Why?
Karnofsky Performance Status
1
2018
36
0.040
 Why?
Structure-Activity Relationship
1
2019
579
0.040
 Why?
Multimodal Imaging
1
2019
120
0.030
 Why?
Fluorescein Angiography
1
2019
175
0.030
 Why?
Colon
1
2020
300
0.030
 Why?
Melanoma
1
2024
772
0.030
 Why?
Half-Life
1
2017
146
0.030
 Why?
RNA
1
2024
930
0.030
 Why?
American Medical Association
1
2017
18
0.030
 Why?
Genome, Human
1
2019
420
0.030
 Why?
Lymphocytes, Tumor-Infiltrating
1
2019
208
0.030
 Why?
Gene Expression Profiling
1
2024
1764
0.030
 Why?
Tomography, Optical Coherence
1
2019
257
0.030
 Why?
Reproducibility of Results
1
2024
3348
0.030
 Why?
Needles
1
2016
63
0.030
 Why?
Delphi Technique
1
2018
308
0.030
 Why?
Radiotherapy, Adjuvant
1
2017
219
0.030
 Why?
Genomic Instability
1
2017
57
0.030
 Why?
Infusions, Intravenous
1
2017
417
0.030
 Why?
Radiotherapy, Intensity-Modulated
1
2017
137
0.030
 Why?
Cell Proliferation
1
2024
2504
0.030
 Why?
Health Services Needs and Demand
1
2018
286
0.030
 Why?
Algorithms
1
2024
1763
0.030
 Why?
Molecular Diagnostic Techniques
1
2017
105
0.030
 Why?
Retreatment
1
2016
73
0.030
 Why?
Meta-Analysis as Topic
1
2017
185
0.030
 Why?
Incidental Findings
1
2016
80
0.030
 Why?
DNA Mutational Analysis
1
2017
398
0.030
 Why?
Acute Disease
1
2019
1008
0.030
 Why?
Platinum
1
2016
51
0.030
 Why?
Gene Frequency
1
2017
494
0.030
 Why?
Serrate-Jagged Proteins
1
2015
27
0.030
 Why?
Jagged-1 Protein
1
2015
23
0.030
 Why?
Neoplasm Invasiveness
1
2017
509
0.030
 Why?
Radiography
2
2016
844
0.030
 Why?
Gene Duplication
1
2015
65
0.030
 Why?
Hematopoietic Stem Cell Transplantation
1
2021
668
0.030
 Why?
Endoscopy, Digestive System
1
2016
135
0.030
 Why?
Tumor Microenvironment
1
2019
692
0.030
 Why?
Magnetic Resonance Imaging
1
2007
3709
0.030
 Why?
Protein Isoforms
1
2016
398
0.030
 Why?
Preoperative Care
1
2017
371
0.030
 Why?
Practice Guidelines as Topic
1
2022
1597
0.030
 Why?
Leukocyte Count
1
2015
328
0.030
 Why?
Analysis of Variance
1
2017
1320
0.030
 Why?
Calcium-Binding Proteins
1
2015
216
0.030
 Why?
Mice, Knockout
1
2021
3068
0.030
 Why?
Ultraviolet Rays
1
2016
401
0.030
 Why?
Societies, Medical
1
2018
855
0.030
 Why?
Protein Processing, Post-Translational
1
2016
464
0.030
 Why?
Behavior, Animal
1
2016
516
0.030
 Why?
CD8-Positive T-Lymphocytes
1
2019
918
0.020
 Why?
Brain Neoplasms
1
2021
1304
0.020
 Why?
Logistic Models
1
2017
2086
0.020
 Why?
Skin
1
2016
765
0.020
 Why?
Immunohistochemistry
1
2016
1737
0.020
 Why?
Follow-Up Studies
1
2020
5200
0.020
 Why?
Cross-Sectional Studies
1
2022
5636
0.020
 Why?
Rats, Sprague-Dawley
1
2016
2520
0.020
 Why?
Lung
1
2023
4134
0.020
 Why?
Protein Binding
1
2016
2239
0.020
 Why?
Angiogenesis Inducing Agents
1
2009
25
0.020
 Why?
Glycogen Synthase Kinase 3 beta
1
2008
73
0.020
 Why?
Glycogen Synthase Kinase 3
1
2008
82
0.020
 Why?
Rats
1
2016
5629
0.020
 Why?
Reference Standards
1
2008
186
0.020
 Why?
Pharmacogenetics
1
2008
167
0.020
 Why?
Breast Neoplasms
1
2019
2250
0.020
 Why?
Infusions, Intra-Arterial
1
1986
61
0.020
 Why?
Hepatic Artery
1
1986
52
0.020
 Why?
Chromatography, High Pressure Liquid
1
2008
593
0.020
 Why?
Mice, Inbred C57BL
1
2016
5887
0.010
 Why?
Predictive Value of Tests
1
2011
2070
0.010
 Why?
Reference Values
1
2007
805
0.010
 Why?
Tomography, X-Ray Computed
1
2016
2746
0.010
 Why?
Tandem Mass Spectrometry
1
2008
566
0.010
 Why?
Image Processing, Computer-Assisted
1
2007
772
0.010
 Why?
Longitudinal Studies
1
2007
2902
0.010
 Why?
Lieu's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
See all (402) concept(s)
_
Co-Authors Expand Description
See all (78) people
_
Similar People Expand Description
See all (60) people
_
Same Department Expand Description
Search Department
Physical Neighbors Expand Description
_

Copyright © 2026 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)